Safety Pharmacology - Risk Assessment QT Interval Prolongation and Beyond
Current regulatory guidelines for cardiac safety utilize hERG block and QT interval prolongation as risk markers. This strategy has been successful at preventing harmful drugs from being marketed, but criticized for leading to early withdrawal of potentially safe drugs. Here we collected a series of...
保存先:
| 主要な著者: | , , , |
|---|---|
| フォーマット: | Online |
| 言語: | 英語 |
| 出版事項: |
Frontiers Media SA
2021
|
| 主題: | |
| オンライン･アクセス: | 31949 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|
| _version_ | 1869523503004254208 |
|---|---|
| author | Stefano Morotti Eleonora Grandi Esther Pueyo Blanca Rodriguez |
| author_browse | Blanca Rodriguez Eleonora Grandi Esther Pueyo Stefano Morotti |
| author_facet | Stefano Morotti Eleonora Grandi Esther Pueyo Blanca Rodriguez |
| author_sort | Stefano Morotti |
| collection | Directory of Open Access Books |
| description | Current regulatory guidelines for cardiac safety utilize hERG block and QT interval prolongation as risk markers. This strategy has been successful at preventing harmful drugs from being marketed, but criticized for leading to early withdrawal of potentially safe drugs. Here we collected a series of articles presenting new technological and conceptual advances, including refinement of ex vivo and in vitro assays, screens and models, and in silico approaches reflecting the increasing effort that has been put forward by regulatory agencies, industry, and academia to try and address the need of a more accurate, mechanistically-based paradigm of proarrhythmic potential of drugs. This Research Topic is dedicated to the memory of Dr. J. Jeremy Rice, our wonderful friend and colleague. |
| format | Online |
| id | doab-20.500.12854ir-58773 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2021 |
| publishDateRange | 2021 |
| publishDateSort | 2021 |
| publisher | Frontiers Media SA |
| publisherStr | Frontiers Media SA |
| record_format | ojs |
| spelling | doab-20.500.12854ir-587732024-03-31T22:45:11Z Safety Pharmacology - Risk Assessment QT Interval Prolongation and Beyond Stefano Morotti Eleonora Grandi Esther Pueyo Blanca Rodriguez QP1-981 Q1-390 cardiotoxicity cardiac electrophysiology. drug-induced arrhythmia QT interval prolongation multi-scale modeling thema EDItEUR::M Medicine and Nursing::MF Pre-clinical medicine: basic sciences::MFG Physiology Current regulatory guidelines for cardiac safety utilize hERG block and QT interval prolongation as risk markers. This strategy has been successful at preventing harmful drugs from being marketed, but criticized for leading to early withdrawal of potentially safe drugs. Here we collected a series of articles presenting new technological and conceptual advances, including refinement of ex vivo and in vitro assays, screens and models, and in silico approaches reflecting the increasing effort that has been put forward by regulatory agencies, industry, and academia to try and address the need of a more accurate, mechanistically-based paradigm of proarrhythmic potential of drugs. This Research Topic is dedicated to the memory of Dr. J. Jeremy Rice, our wonderful friend and colleague. 2021-02-12T02:43:46Z 2021-02-12T02:43:46Z 2019-01-23 14:53:42 2018 book 31949 16648714 9782889455393 https://directory.doabooks.org/handle/20.500.12854/58773 eng Frontiers Research Topics image/jpeg Attribution 4.0 International https://www.frontiersin.org/research-topics/5662/safety-pharmacology---risk-assessment-qt-interval-prolongation-and-beyond Frontiers Media SA 10.3389/978-2-88945-539-3 10.3389/978-2-88945-539-3 bf5ce210-e72e-4860-ba9b-c305640ff3ae 9782889455393 385 open access |
| spellingShingle | QP1-981 Q1-390 cardiotoxicity cardiac electrophysiology. drug-induced arrhythmia QT interval prolongation multi-scale modeling thema EDItEUR::M Medicine and Nursing::MF Pre-clinical medicine: basic sciences::MFG Physiology Stefano Morotti Eleonora Grandi Esther Pueyo Blanca Rodriguez Safety Pharmacology - Risk Assessment QT Interval Prolongation and Beyond |
| title | Safety Pharmacology - Risk Assessment QT Interval Prolongation and Beyond |
| title_full | Safety Pharmacology - Risk Assessment QT Interval Prolongation and Beyond |
| title_fullStr | Safety Pharmacology - Risk Assessment QT Interval Prolongation and Beyond |
| title_full_unstemmed | Safety Pharmacology - Risk Assessment QT Interval Prolongation and Beyond |
| title_short | Safety Pharmacology - Risk Assessment QT Interval Prolongation and Beyond |
| title_sort | safety pharmacology risk assessment qt interval prolongation and beyond |
| topic | QP1-981 Q1-390 cardiotoxicity cardiac electrophysiology. drug-induced arrhythmia QT interval prolongation multi-scale modeling thema EDItEUR::M Medicine and Nursing::MF Pre-clinical medicine: basic sciences::MFG Physiology |
| topic_facet | QP1-981 Q1-390 cardiotoxicity cardiac electrophysiology. drug-induced arrhythmia QT interval prolongation multi-scale modeling thema EDItEUR::M Medicine and Nursing::MF Pre-clinical medicine: basic sciences::MFG Physiology |
| url | 31949 |
| work_keys_str_mv | AT stefanomorotti safetypharmacologyriskassessmentqtintervalprolongationandbeyond AT eleonoragrandi safetypharmacologyriskassessmentqtintervalprolongationandbeyond AT estherpueyo safetypharmacologyriskassessmentqtintervalprolongationandbeyond AT blancarodriguez safetypharmacologyriskassessmentqtintervalprolongationandbeyond |